← Back to Screener
Nanobiotix S.A. American Depositary Shares (NBTX)
Price$31.91
Favorite Metrics
Price vs S&P 500 (26W)6.84%
Price vs S&P 500 (4W)-1.97%
Market Capitalization$1.64B
All Metrics
Book Value / Share (Quarterly)$0.06
P/TBV (Annual)9.50x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.83
Price vs S&P 500 (YTD)39.02%
Net Profit Margin (TTM)-80.84%
EPS (TTM)$-0.59
10-Day Avg Trading Volume0.17M
EPS Excl Extra (TTM)$-0.59
Revenue Growth (5Y)258.58%
EPS (Annual)$-0.59
ROI (Annual)-67.39%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-122461.58%
Cash / Share (Quarterly)$1.28
Revenue Growth QoQ (YoY)304.48%
ROA (Last FY)-35.36%
Revenue Growth TTM (YoY)-80.24%
EBITD / Share (TTM)$-0.24
ROE (5Y Avg)-124.29%
Operating Margin (TTM)-38.11%
Cash Flow / Share (Annual)$-0.83
P/B Ratio774.93x
P/B Ratio (Quarterly)65.40x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)48.28x
Net Interest Coverage (TTM)-0.89x
ROA (TTM)-42.44%
EPS Incl Extra (Annual)$-0.59
Current Ratio (Annual)1.09x
Quick Ratio (Quarterly)1.05x
3-Month Avg Trading Volume0.20M
52-Week Price Return854.91%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.06
P/S Ratio (Annual)46.85x
Asset Turnover (Annual)0.44x
52-Week High$35.20
Operating Margin (5Y Avg)-133512.98%
EPS Excl Extra (Annual)$-0.59
CapEx CAGR (5Y)38.54%
Tangible BV CAGR (5Y)11.42%
26-Week Price Return15.58%
Quick Ratio (Annual)1.05x
13-Week Price Return50.11%
Total Debt / Equity (Annual)1.60x
Current Ratio (Quarterly)1.09x
Enterprise Value$1,685.891
Revenue / Share Growth (5Y)211.90%
Asset Turnover (TTM)0.53x
Book Value / Share Growth (5Y)-6.95%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-80.83%
Cash / Share (Annual)$1.28
3-Month Return Std Dev74.41%
Net Income / Employee (TTM)$-0
ROE (Last FY)-175.45%
Net Interest Coverage (Annual)-0.89x
EPS Basic Excl Extra (Annual)$-0.59
Receivables Turnover (TTM)11.60x
Total Debt / Equity (Quarterly)23.58x
EPS Incl Extra (TTM)$-0.59
Receivables Turnover (Annual)11.60x
ROI (TTM)-75.47%
P/S Ratio (TTM)46.85x
Pretax Margin (5Y Avg)-122447.02%
Revenue / Share (Annual)$0.73
Tangible BV / Share (Annual)$0.91
Price vs S&P 500 (52W)819.81%
Year-to-Date Return42.26%
5-Day Price Return-0.50%
EPS Normalized (Annual)$-0.59
ROA (5Y Avg)-64.07%
Net Profit Margin (Annual)-80.84%
Month-to-Date Return7.31%
Cash Flow / Share (TTM)$-1.93
EBITD / Share (Annual)$-0.25
Operating Margin (Annual)-38.11%
LT Debt / Equity (Annual)1.13x
ROI (5Y Avg)-68.91%
LT Debt / Equity (Quarterly)16.13x
EPS Basic Excl Extra (TTM)$-0.59
P/TBV (Quarterly)65.43x
P/B Ratio (Annual)9.50x
Pretax Margin (TTM)-80.83%
Book Value / Share (Annual)$0.91
Price vs S&P 500 (13W)47.24%
Beta1.00x
Revenue / Share (TTM)$0.72
ROE (TTM)-300.48%
52-Week Low$2.79
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NBTXNanobiotix S.A. American Depositary Shares | 46.85x | -80.24% | — | — | $31.91 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Nanobiotix SA is a clinical-stage biotechnology company developing proprietary nanotechnology to enhance the effectiveness of cancer radiotherapy. Its NanoXray platform amplifies radiation effects within tumor cells without increasing exposure to surrounding healthy tissue. The company's lead candidate, NBTXR3, is being evaluated for cancer immunotherapy applications.